68 research outputs found
Primary dermal melanoma in a patient with a history of multiple malignancies: a case report with molecular characterization
Introduction: Primary dermal melanoma (PDM) is a recently described clinical entity accounting for less than 1% of all melanomas. Histologically, it is located in the dermis or subcutaneous tissue, and it shows no connections with the overlying epidermis. The differential diagnosis is principally made along with that of metastatic cutaneous melanoma.
Case Report: A 72-year-old Caucasian woman with a history of multiple cancers (metachro-nous bilateral breast cancer, meningioma, clear cell renal cell carcinoma, uterine fibromatosis and intestinal adenomatous polyposis), came to our attention with a nodular lesion on her back. After removal of the lesion, the histology report indicated malignant PDM or metastatic malignant melanoma. The clinical and instrumental evaluation of the patient did not reveal any other primary tumour, suggesting the primitive nature of the lesion. The absence of an epithelial component argued for a histological diagnosis of PDM. Subsequently, the patient underwent a wide surgical excision with sentinel node biopsy, which was positive for metastatic melanoma. Finally, the mutational status was studied in the main genes that regulate proliferation, apoptosis and cellular senescence. No pathogenetic mutations in CDKN2A, BRAF, NRAS, KRAS, cKIT, TP53 and PTEN genes were observed. This suggests that alternative pathways and low-frequency alterations may be involved.
Conclusions: The differential diagnosis between PDM and isolated metastatic melanoma depends on the negativity of imaging studies and clinical findings for other primary lesions. This distinction is important because 5-year survival rates in such cases are higher than in metastatic cases (80â 100 vs. 5â20%, respectively)
Epidemiology and Genetic Susceptibility of Breast and Ovarian Cancer in Sardinian Population
The objective of this population-based study is to describe epidemiological and genetic features of breast and ovarian cancer in North Sardinia, Italy. Patients who carry a high-risk mutation in one or both of the BRCA genes (BRCA1 or BRCA2) have a significantly increased risk of developing breast/ovarian cancer (BOC) and other cancers (e.g., prostate cancer in male). Epidemiological data on incidence distribution of breast/ovarian cancer from 2016 to 2019Â in North Sardinia are obtained from the local tumor registry and from the cumulative results of 209 genetic testing for BRCA gene mutations performed in all young breast cancer patients and all women (over 50Â years) with family history of BOC (total of 164 cases); further, 45 genetic testing is performed, on ovarian cancer patients, at any age. The results provide a different distribution of fraction mutations carried by women and a higher prevalence of the BRCA2 mutation in the north of Sardinia than the entire population and highlight the presence of specific germline mutation associated with the âfounder effectâ in distinct genetic subgroups reflecting genetic drift. Advances in next-generation sequencing technology, data analysis, and clinical investigation have revolutionized efforts to identify potential targets for BRCA molecular-based therapeutic agents
Origin and distribution of the BRCA2-8765delAG mutation in breast cancer
Background: The BRCA2-8765delAG mutation was firstly described in breast cancer families from
French-Canadian and Jewish-Yemenite populations; it was then reported as a founder mutation in
Sardinian families. We evaluated both the prevalence of the BRCA2-8765delAG variant in Sardinia
and the putative existence of a common ancestral origin through a haplotype analysis of breast
cancer family members carrying such a mutation.
Methods: Eight polymorphic microsatellite markers (D13S1250, centromeric, to D13S267,
telomeric) spanning the BRCA2 gene locus were used for the haplotype analysis. Screening for the
8765delAG mutation was performed by PCR-based amplification of BRCA2-exon 20, followed by
automated sequencing.
Results: Among families with high recurrence of breast cancer (â„ 3 cases in first-degree relatives),
those from North Sardinia shared the same haplotype whereas the families from French Canadian
and Jewish-Yemenite populations presented distinct genetic assets at the BRCA2 locus. Screening
for the BRCA2-8765delAG variant among unselected and consecutively-collected breast cancer
patients originating from the entire Sardinia revealed that such a mutation is present in the
northern part of the island only [9/648 (1.4%) among cases from North Sardinia versus 0/493
among cases from South Sardinia].
Conclusion: The BRCA2-8765delAG has an independent origin in geographically and ethnically
distinct populations, acting as a founder mutation in North but not in South Sardinia. Since BRCA2-
8765delAG occurs within a triplet repeat sequence of AGAGAG, our study further confirmed the
existence of a mutational hot-spot at this genomic position (additional genetic factors within each
single population might be involved in generating such a mutation)
Role of BRCA2 mutation status on overall survival among breast cancer patients from Sardinia
Background: Germline mutations in BRCA1 or BRCA2 genes have been demonstrated to increase
the risk of developing breast cancer. Conversely, the impact of BRCA mutations on prognosis and
survival of breast cancer patients is still debated. In this study, we investigated the role of such
mutations on breast cancer-specific survival among patients from North Sardinia.
Methods: Among incident cases during the period 1997â2002, a total of 512 breast cancer
patients gave their consent to undergo BRCA mutation screening by DHPLC analysis and automated
DNA sequencing. The Hakulinen, Kaplan-Meier, and Cox regression methods were used for both
relative survival assessment and statistical analysis.
Results: In our series, patients carrying a germline mutation in coding regions and splice
boundaries of BRCA1 and BRCA2 genes were 48/512 (9%). Effect on overall survival was evaluated
taking into consideration BRCA2 carriers, who represented the vast majority (44/48; 92%) of
mutation-positive patients. A lower breast cancer-specific overall survival rate was observed in
BRCA2 mutation carriers after the first two years from diagnosis. However, survival rates were
similar in both groups after five years from diagnosis. No significant difference was found for age of
onset, disease stage, and primary tumour histopathology between the two subsets.
Conclusion: In Sardinian breast cancer population, BRCA2 was the most affected gene and the
effects of BRCA2 germline mutations on patients' survival were demonstrated to vary within the
first two years from diagnosis. After a longer follow-up observation, breast cancer-specific rates of
death were instead similar for BRCA2 mutation carriers and non-carriers
Evaluating the impact of different sequence databases on metaproteome analysis: insights from a lab-assembled microbial mixture
Metaproteomics enables the investigation of the protein repertoire expressed by complex microbial communities. However, to unleash its full potential, refinements in bioinformatic approaches for data analysis are still needed. In this context, sequence databases selection represents a major challenge.
This work assessed the impact of different databases in metaproteomic investigations by using a mock microbial mixture including nine diverse bacterial and eukaryotic species, which was subjected to shotgun metaproteomic analysis. Then, both the microbial mixture and the single microorganisms were subjected to next generation sequencing to obtain experimental metagenomic- and genomic-derived databases, which were used along with public databases (namely, NCBI, UniProtKB/SwissProt and UniProtKB/TrEMBL, parsed at different taxonomic levels) to analyze the metaproteomic dataset. First, a quantitative comparison in terms of number and overlap of peptide identifications was carried out among all databases. As a result, only 35% of peptides were common to all database classes; moreover, genus/species-specific databases provided up to 17% more identifications compared to databases with generic taxonomy, while the metagenomic database enabled a slight increment in respect to public databases. Then, database behavior in terms of false discovery rate and peptide degeneracy was critically evaluated. Public databases with generic taxonomy exhibited a markedly different trend compared to the counterparts. Finally, the reliability of taxonomic attribution according to the lowest common ancestor approach (using MEGAN and Unipept software) was assessed. The level of misassignments varied among the different databases, and specific thresholds based on the number of taxon-specific peptides were established to minimize false positives. This study confirms that database selection has a significant impact in metaproteomics, and provides critical indications for improving depth and reliability of metaproteomic results. Specifically, the use of iterative searches and of suitable filters for taxonomic assignments is proposed with the aim of increasing coverage and trustworthiness of metaproteomic data.</br
Role of the <i>EGF</i> +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls
Background. A single nucleotide polymorphism (61A>G) in the epidermal growth factor (EGF) gene has been implicated in both melanoma pathogenesis and increased melanoma risk. To further evaluate this association, we conducted a case-control study in a clinic-based Italian population.
Methods. Individuals with less than 10 (N = 127) or more than 100 (N = 128) benign nevi, and patients with cutaneous melanoma (N = 418) were investigated for the EGF +61A>G polymorphism, using an automated sequencing approach.
Results. Overall, no difference in EGF genotype frequencies was observed among subjects with different number of nevi as well as when non-melanoma healthy controls were compared with the melanoma patients. However, a heterogeneous distribution of the frequencies of the G/G genotype was detected among cases and controls originating from North Italy (21.1 and 18.3%, respectively) vs. those from South Italy (12.6 and 17.1%, respectively).
Conclusion. Our findings further suggest that EGF +61A>G polymorphism may have a limited impact on predisposition and/or pathogenesis of melanoma and its prevalence may vary in different populations
Role of the EGF +61A>G polymorphism in melanoma pathogenesis: an experience on a large series of Italian cases and controls
<p>Abstract</p> <p>Background</p> <p>A single nucleotide polymorphism (61A>G) in the epidermal growth factor (<it>EGF</it>) gene has been implicated in both melanoma pathogenesis and increased melanoma risk. To further evaluate this association, we conducted a case-control study in a clinic-based Italian population.</p> <p>Methods</p> <p>Individuals with less than 10 (N = 127) or more than 100 (N = 128) benign nevi, and patients with cutaneous melanoma (N = 418) were investigated for the <it>EGF </it>+61A>G polymorphism, using an automated sequencing approach.</p> <p>Results</p> <p>Overall, no difference in <it>EGF </it>genotype frequencies was observed among subjects with different number of nevi as well as when non-melanoma healthy controls were compared with the melanoma patients. However, a heterogeneous distribution of the frequencies of the G/G genotype was detected among cases and controls originating from North Italy (21.1 and 18.3%, respectively) vs. those from South Italy (12.6 and 17.1%, respectively).</p> <p>Conclusion</p> <p>Our findings further suggest that <it>EGF </it>+61A>G polymorphism may have a limited impact on predisposition and/or pathogenesis of melanoma and its prevalence may vary in different populations.</p
Prevalence of <i>KRAS</i>, <i>BRAF</i>, and <i>PIK3CA</i> somatic mutations in patients with colorectal carcinoma may vary in the same population: clues from Sardinia
Background
Role of KRAS, BRAF and PIK3CA mutations in pathogenesis of colorectal cancer (CRC) has
been recently investigated worldwide. In this population-based study, we evaluated the incidence rates and distribution of such somatic mutations in genetically isolated population from Sardinia.
Methods
From April 2009 to July 2011, formalin-fixed paraffin-embedded tissues (N = 478) were prospectively collected from Sardinian CRC patients at clinics across the entire island. Genomic DNA was isolated from tissue sections and screened for mutations in KRAS, BRAF,
and PIK3CA genes by automated DNA sequencing.
Results
Overall, KRAS tumour mutation rate was 30% (145/478 positive cases). Distribution of mutation carriers was surprisingly different within the island: 87/204 (43%) in North Sardinia vs. 58/274 (21%) in Middle-South Sardinia (p<0.001). Among 384 CRC cases whose DNA
was available, only one (0.3%) patient carried a mutation in BRAF gene; PIK3CA was found mutated in 67 (17%) patients. A significant inverse distribution of PIK3CA mutation rates was observed within Sardinian population: 19/183 (10%) cases from northern vs. 48/201 (24%) cases from central-southern island (p<0.001). This heterogeneity in frequencies of
KRAS/PIK3CA somatic mutations is consistent with already-reported discrepancies in distribution of germline mutations for other malignancies within Sardinian population. Preliminary clinical evaluation of 118 KRAS wild-type patients undergoing anti-EGFR-based
treatment indicated lack of role for PIK3CA in predicting response to therapy.
Conclusions
Our findings support the hypothesis that differences in patientsâ origins and related genetic backgrounds may contribute to even determine the incidence rate of somatic mutations in candidate cancer genes.</br
Genome-wide association study of susceptibility loci for breast cancer in Sardinian population
Abstract
Background
Despite progress in identifying genes associated with breast cancer, many more risk loci exist. Genome-wide association analyses in genetically-homogeneous populations, such as that of Sardinia (Italy), could represent an additional approach to detect low penetrance alleles.
Methods
We performed a genome-wide association study comparing 1431 Sardinian patients with non-familial, BRCA1/2-mutation-negative breast cancer to 2171 healthy Sardinian blood donors. DNA was genotyped using GeneChip Human Mapping 500Â K Arrays or Genome-Wide Human SNP Arrays 6.0. To increase genomic coverage, genotypes of additional SNPs were imputed using data from HapMap Phase II. After quality control filtering of genotype data, 1367 cases (9 men) and 1658 controls (1156 men) were analyzed on a total of 2,067,645 SNPs.
Results
Overall, 33 genomic regions (67 candidate SNPs) were associated with breast cancer risk at the pâ<â10â6 level. Twenty of these regions contained defined genes, including one already associated with breast cancer risk: TOX3. With a lower threshold for preliminary significance to pâ<â10â5, we identified 11 additional SNPs in FGFR2, a well-established breast cancer-associated gene. Ten candidate SNPs were selected, excluding those already associated with breast cancer, for technical validation as well as replication in 1668 samples from the same population. Only SNP rs345299, located in intron 1 of VAV3, remained suggestively associated (p-value, 1.16x10â5), but it did not associate with breast cancer risk in pooled data from two large, mixed-population cohorts.
Conclusions
This study indicated the role of TOX3 and FGFR2 as breast cancer susceptibility genes in BRCA1/2-wild-type breast cancer patients from Sardinian population
Genome-wide association study of susceptibility loci for breast cancer in Sardinian population.
BACKGROUND: Despite progress in identifying genes associated with breast cancer, many more risk loci exist. Genome-wide association analyses in genetically-homogeneous populations, such as that of Sardinia (Italy), could represent an additional approach to detect low penetrance alleles. METHODS: We performed a genome-wide association study comparing 1431 Sardinian patients with non-familial, BRCA1/2-mutation-negative breast cancer to 2171 healthy Sardinian blood donors. DNA was genotyped using GeneChip Human Mapping 500 K Arrays or Genome-Wide Human SNP Arrays 6.0. To increase genomic coverage, genotypes of additional SNPs were imputed using data from HapMap Phase II. After quality control filtering of genotype data, 1367 cases (9 men) and 1658 controls (1156 men) were analyzed on a total of 2,067,645 SNPs. RESULTS: Overall, 33 genomic regions (67 candidate SNPs) were associated with breast cancer risk at the p <â 0(-6) level. Twenty of these regions contained defined genes, including one already associated with breast cancer risk: TOX3. With a lower threshold for preliminary significance to p < 10(-5), we identified 11 additional SNPs in FGFR2, a well-established breast cancer-associated gene. Ten candidate SNPs were selected, excluding those already associated with breast cancer, for technical validation as well as replication in 1668 samples from the same population. Only SNP rs345299, located in intron 1 of VAV3, remained suggestively associated (p-value, 1.16 x 10(-5)), but it did not associate with breast cancer risk in pooled data from two large, mixed-population cohorts. CONCLUSIONS: This study indicated the role of TOX3 and FGFR2 as breast cancer susceptibility genes in BRCA1/2-wild-type breast cancer patients from Sardinian population
- âŠ